260 related articles for article (PubMed ID: 27692237)
1. An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility.
Martinez AF; Abe Y; Hong S; Molyneux K; Yarnell D; Löhr H; Driever W; Acosta MT; Arcos-Burgos M; Muenke M
Biol Psychiatry; 2016 Dec; 80(12):943-954. PubMed ID: 27692237
[TBL] [Abstract][Full Text] [Related]
2. ADGRL3 rs6551665 as a Common Vulnerability Factor Underlying Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.
Kappel DB; Schuch JB; Rovaris DL; da Silva BS; Müller D; Breda V; Teche SP; S Riesgo R; Schüler-Faccini L; Rohde LA; Grevet EH; Bau CHD
Neuromolecular Med; 2019 Mar; 21(1):60-67. PubMed ID: 30652248
[TBL] [Abstract][Full Text] [Related]
3. Brain structural and functional substrates of ADGRL3 (latrophilin 3) haplotype in attention-deficit/hyperactivity disorder.
Moreno-Alcázar A; Ramos-Quiroga JA; Ribases M; Sánchez-Mora C; Palomar G; Bosch R; Salavert J; Fortea L; Monté-Rubio GC; Canales-Rodríguez EJ; Milham MP; Castellanos FX; Casas M; Pomarol-Clotet E; Radua J
Sci Rep; 2021 Jan; 11(1):2373. PubMed ID: 33504901
[TBL] [Abstract][Full Text] [Related]
4. Expression of the adult ADHD-associated gene
McNeill RV; Palladino VS; Brunkhorst-Kanaan N; Grimm O; Reif A; Kittel-Schneider S
World J Biol Psychiatry; 2021 Jun; 22(5):335-349. PubMed ID: 32787626
[TBL] [Abstract][Full Text] [Related]
5. LPHN3 and attention-deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study.
Bruxel EM; Salatino-Oliveira A; Akutagava-Martins GC; Tovo-Rodrigues L; Genro JP; Zeni CP; Polanczyk GV; Chazan R; Schmitz M; Arcos-Burgos M; Rohde LA; Hutz MH
Genes Brain Behav; 2015 Jun; 14(5):419-27. PubMed ID: 25989180
[TBL] [Abstract][Full Text] [Related]
6. A common variant of the latrophilin 3 gene, LPHN3, confers susceptibility to ADHD and predicts effectiveness of stimulant medication.
Arcos-Burgos M; Jain M; Acosta MT; Shively S; Stanescu H; Wallis D; Domené S; Vélez JI; Karkera JD; Balog J; Berg K; Kleta R; Gahl WA; Roessler E; Long R; Lie J; Pineda D; Londoño AC; Palacio JD; Arbelaez A; Lopera F; Elia J; Hakonarson H; Johansson S; Knappskog PM; Haavik J; Ribases M; Cormand B; Bayes M; Casas M; Ramos-Quiroga JA; Hervas A; Maher BS; Faraone SV; Seitz C; Freitag CM; Palmason H; Meyer J; Romanos M; Walitza S; Hemminger U; Warnke A; Romanos J; Renner T; Jacob C; Lesch KP; Swanson J; Vortmeyer A; Bailey-Wilson JE; Castellanos FX; Muenke M
Mol Psychiatry; 2010 Nov; 15(11):1053-66. PubMed ID: 20157310
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of impulsivity and aggression in mice deficient for the ADHD risk gene Adgrl3: Evidence for dopamine transporter dysregulation.
Mortimer N; Ganster T; O'Leary A; Popp S; Freudenberg F; Reif A; Soler Artigas M; Ribasés M; Ramos-Quiroga JA; Lesch KP; Rivero O
Neuropharmacology; 2019 Sep; 156():107557. PubMed ID: 30849401
[TBL] [Abstract][Full Text] [Related]
8. Genetic Variation Underpinning ADHD Risk in a Caribbean Community.
Puentes-Rozo PJ; Acosta-López JE; Cervantes-Henríquez ML; Martínez-Banfi ML; Mejia-Segura E; Sánchez-Rojas M; Anaya-Romero ME; Acosta-Hoyos A; García-Llinás GA; Mastronardi CA; Pineda DA; Castellanos FX; Arcos-Burgos M; Vélez JI
Cells; 2019 Aug; 8(8):. PubMed ID: 31426340
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis and systematic review of ADGRL3 (LPHN3) polymorphisms in ADHD susceptibility.
Bruxel EM; Moreira-Maia CR; Akutagava-Martins GC; Quinn TP; Klein M; Franke B; Ribasés M; Rovira P; Sánchez-Mora C; Kappel DB; Mota NR; Grevet EH; Bau CHD; Arcos-Burgos M; Rohde LA; Hutz MH
Mol Psychiatry; 2021 Jun; 26(6):2277-2285. PubMed ID: 32051549
[TBL] [Abstract][Full Text] [Related]
10. ADGRL3 (LPHN3) variants predict substance use disorder.
Arcos-Burgos M; Vélez JI; Martinez AF; Ribasés M; Ramos-Quiroga JA; Sánchez-Mora C; Richarte V; Roncero C; Cormand B; Fernández-Castillo N; Casas M; Lopera F; Pineda DA; Palacio JD; Acosta-López JE; Cervantes-Henriquez ML; Sánchez-Rojas MG; Puentes-Rozo PJ; Molina BSG; ; Boden MT; Wallis D; Lidbury B; Newman S; Easteal S; Swanson J; Patel H; Volkow N; Acosta MT; Castellanos FX; de Leon J; Mastronardi CA; Muenke M
Transl Psychiatry; 2019 Jan; 9(1):42. PubMed ID: 30696812
[TBL] [Abstract][Full Text] [Related]
11. Adhesion G protein-coupled receptor L3 gene variants: Statistically significant association observed in the male Indo-caucasoid Attention deficit hyperactivity disorder probands.
Chatterjee M; Saha S; Shom S; Sinha S; Mukhopadhyay K
Mol Biol Rep; 2021 Apr; 48(4):3213-3222. PubMed ID: 33914279
[TBL] [Abstract][Full Text] [Related]
12. Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study.
Ribasés M; Ramos-Quiroga JA; Sánchez-Mora C; Bosch R; Richarte V; Palomar G; Gastaminza X; Bielsa A; Arcos-Burgos M; Muenke M; Castellanos FX; Cormand B; Bayés M; Casas M
Genes Brain Behav; 2011 Mar; 10(2):149-57. PubMed ID: 21040458
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning Prediction of ADHD Severity: Association and Linkage to
Cervantes-Henríquez ML; Acosta-López JE; Martinez AF; Arcos-Burgos M; Puentes-Rozo PJ; Vélez JI
J Atten Disord; 2022 Feb; 26(4):587-605. PubMed ID: 34009035
[TBL] [Abstract][Full Text] [Related]
14. LPHN3 gene variations and susceptibility to ADHD in Chinese Han population: a two-stage case-control association study and gene-environment interactions.
Huang X; Zhang Q; Gu X; Hou Y; Wang M; Chen X; Wu J
Eur Child Adolesc Psychiatry; 2019 Jun; 28(6):861-873. PubMed ID: 30406846
[TBL] [Abstract][Full Text] [Related]
15. CDH13 and LPHN3 Gene Polymorphisms in Attention-Deficit/Hyperactivity Disorder: Their Relation to Clinical Characteristics.
Özaslan A; Güney E; Ergün MA; Okur İ; Yapar D
J Mol Neurosci; 2021 Feb; 71(2):394-408. PubMed ID: 32691279
[TBL] [Abstract][Full Text] [Related]
16. Influence of a latrophilin 3 (LPHN3) risk haplotype on event-related potential measures of cognitive response control in attention-deficit hyperactivity disorder (ADHD).
Fallgatter AJ; Ehlis AC; Dresler T; Reif A; Jacob CP; Arcos-Burgos M; Muenke M; Lesch KP
Eur Neuropsychopharmacol; 2013 Jun; 23(6):458-68. PubMed ID: 23245769
[TBL] [Abstract][Full Text] [Related]
17. Further replication of the synergistic interaction between LPHN3 and the NTAD gene cluster on ADHD and its clinical course throughout adulthood.
Kappel DB; Schuch JB; Rovaris DL; da Silva BS; Cupertino RB; Winkler C; Teche SP; Vitola ES; Karam RG; Rohde LA; Bau CHD; Grevet EH; Mota NR
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):120-127. PubMed ID: 28624582
[TBL] [Abstract][Full Text] [Related]
18. Screening of human LPHN3 for variants with a potential impact on ADHD susceptibility.
Domené S; Stanescu H; Wallis D; Tinloy B; Pineda DE; Kleta R; Arcos-Burgos M; Roessler E; Muenke M
Am J Med Genet B Neuropsychiatr Genet; 2011 Jan; 156B(1):11-8. PubMed ID: 21184580
[TBL] [Abstract][Full Text] [Related]
19. LPHN3 and attention-deficit/hyperactivity disorder: interaction with maternal stress during pregnancy.
Choudhry Z; Sengupta SM; Grizenko N; Fortier ME; Thakur GA; Bellingham J; Joober R
J Child Psychol Psychiatry; 2012 Aug; 53(8):892-902. PubMed ID: 22486528
[TBL] [Abstract][Full Text] [Related]
20. Convergent selective signaling impairment exposes the pathogenicity of latrophilin-3 missense variants linked to inheritable ADHD susceptibility.
Moreno-Salinas AL; Holleran BJ; Ojeda-Muñiz EY; Correoso-Braña KG; Ribalta-Mena S; Ovando-Zambrano JC; Leduc R; Boucard AA
Mol Psychiatry; 2022 May; 27(5):2425-2438. PubMed ID: 35393556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
